Cardiovascular Pharmacotherapy Focus
نویسندگان
چکیده
منابع مشابه
Pharmacotherapy of HIV: Focus on Etravirine
Etravirine (ETR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) designed for binding to HIV reverse transcriptase in spite of most of the mutations which normally confer resistance to the other drugs of the same class. Evidences from clinical trials and post-marketing drug use provide guidance for the use of the drug in NNRTI-experienced patients. However, despite the raised ...
متن کاملPharmacotherapy in cardiovascular diseases and vascular interventions.
1172 The current theme issue of Thrombosis and Haemostasis focuses on antiplatelet, anticoagulative and antithrombotic pharmacotherapy in patients with atherothrombotic diseases and especially those undergoing vascular interventions. This topic is of central importance to the majority of patients treated in most clinical disciplines, but especially in the areas of cardiology, neurology and angi...
متن کاملOptimizing Pharmacotherapy for Limiting Cardiovascular Remodeling
Cardiovascular remodeling is a major mechanism leading to adverse outcome. The renin-angiotensin-aldosterone system (RAAS), with angiotensin II as its primary effector peptide, plays an important regulatory role in cardiovascular remodeling. Most angiotensin II is formed via the angiotensin-converting enzyme (ACE) pathway, providing rationale for use of ACE inhibitors. Hypertension and myocardi...
متن کاملPharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant
This article reviews the role of vernakalant in the management of atrial fi brillation (AF). Published data in English language were identifi ed from MEDLINE and Current Content database (both 1966 to January 30, 2009). Vernakalant is an antiarrhythmic agent with sodium and ultra-rapid potassium channel blockage property and atrial selective effect. In clinical studies evaluating intravenous ve...
متن کاملPharmacotherapy of Paget’s Disease of Bone: Focus on Zoledronic Acid
Paget’s disease of bone (PDB) affects 1%–3% of the population and is associated with increased risk for bone fracture and deformity. Increased osteoclastic activity is the principal characteristic of PDB. Bisphosphonates inhibit osteoclastic activity and represent the mainstay of treatment of PDB. Zoledronic acid, a potent member of this class, normalizes serum alkaline phosphatase (ALP) levels...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Cardiology Review
سال: 2019
ISSN: 1758-3764,1758-3756
DOI: 10.15420/ecr.2019.14.2.ge1